Hillel Galitzer - 28 Apr 2025 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Role
Chief Operating Officer
Signature
/s/ Dana Yaacov-Garbeli, Attorney-in-fact
Issuer symbol
ENTX
Transactions as of
28 Apr 2025
Net transactions value
$0
Form type
4
Filing time
30 Apr 2025, 16:22:04 UTC
Previous filing
23 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENTX Ordinary Shares, par value NIS 0.0000769 per share Award $0 +26,316 +41% $0.000000 90,573 28 Apr 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTX Stock Option (right to buy) Award $0 +100,000 $0.000000 100,000 28 Apr 2025 Ordinary Shares, par value NIS 0.0000769 per share 100,000 $2.28 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of stock-settled restricted stock units. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 28, 2025.
F2 The options vest over a three-year period with 33% of the options vesting on April 28, 2025, the first anniversary of the vesting commencement date, and the remaining options vesting ratably on a quarterly basis over the remaining three-year period.